← All organizations

MorphoSys

For profitContributed to NME

Also known as: Morphosys | MorphoSys AG | MorphoSys US Inc. | MORPHOSYS US INC

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Jan 31, 2024

Acquired by Novartis on Feb 6, 2024

Timeline

1990s

Jan 1, 1992
MorphoSys— Founded

2010s

Jan 1, 2013
Sloning BioTechnology— Acquired
Jan 1, 2015
Lanthio Pharma— Acquired

2020s

Jul 31, 2020
tafasitamab— Marketing Organization
Jul 31, 2020
tafasitamab— NDA Organization
Jul 31, 2020
tafasitamab— NDA Secondary Org
Jun 3, 2021
Constellation Pharmaceuticals— Acquired
Feb 6, 2024
Novartis— Acquired By

Drugs by trial phase (29 distinct, 35 trials)

Phase 3 (7 own, 3 via acquisition)

Phase 2 (9 own, 6 via acquisition)

Phase 1 (3 own, 1 via acquisition)

Marketed drugs (1)

tafasitamab

Subsidiaries (3 direct, 3 total across the full acquisition tree)

Recent trials (28)

NCT04300803Lead sponsorN/A—
NCT06029309CollaboratorPhase 1/Phase 2Jan 31, 2024
NCT05942300CollaboratorPhase 1Dec 31, 2023
NCT05944562CollaboratorPhase 1Dec 31, 2023
NCT05626322CollaboratorPhase 2Dec 7, 2022
NCT05222555Lead sponsorPhase 1/Phase 2Jul 19, 2022
NCT05021484CollaboratorPhase 2Oct 31, 2021
NCT04893096CollaboratorPhase 2Oct 31, 2021
NCT05065970Lead sponsorPhase 2Aug 31, 2021
NCT04824092Study directorPhase 3May 11, 2021
NCT04824092Lead sponsorPhase 3May 11, 2021
NCT04733040Lead sponsorPhase 2Jan 20, 2021
NCT04134936Study directorPhase 1Nov 30, 2019
NCT04134936Lead sponsorPhase 1Nov 30, 2019
NCT04145440Lead sponsorPhase 1/Phase 2Oct 15, 2019

Details

Founded: Martinsried, DE Jan 1, 1992
First NDA: Jul 31, 2020
Last known activity: Jan 31, 2024

Designations held

Orphan drug
Fast track
Priority review
Breakthrough therapy
Accelerated approval